Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2013 - 2026)

Amphastar Pharmaceuticals' EPS (Basic) history runs 14 years deep, the most recent figure standing at $0.14 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 73.58% year-over-year to $0.14; the TTM figure through Mar 2026 stood at $1.71 (down 41.44% YoY), while the FY2025 annual figure was $2.1, down 36.17% from the prior year.
• EPS (Basic) was $0.14 for Q1 2026 at Amphastar Pharmaceuticals, down from $0.53 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $1.01 in Q3 2023 to a low of $0.14 in Q1 2026.
• Historically, EPS (Basic) has averaged $0.6 across 5 years, with a median of $0.54 in 2023.
• The sharpest annual moves came in 2022 and 2026: EPS (Basic) soared 354.55% in 2022, then tumbled 73.58% in 2026.
• A 5-year view of EPS (Basic) shows it stood at $0.7 in 2022, then grew by 7.14% to $0.75 in 2023, then advanced by 5.33% to $0.79 in 2024, then sank by 32.91% to $0.53 in 2025, then sank by 73.58% to $0.14 in 2026.
• The last three EPS (Basic) figures came in at $0.14 (Q1 2026), $0.53 (Q4 2025), and $0.38 (Q3 2025), per Business Quant data.